DIADEXUS INC (DDXS)
(Delayed Data from OTC)
$0.01 USD
-0.01 (-35.00%)
Updated Jun 21, 2016 02:15 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
diaDexus Inc. [DDXS]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: diaDexus Inc.
Industry: Medical - Products
We are dropping coverage of Diadexus, Inc. Our previous rating was HOLD and our price target was $4.20.
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 10.00
Company: diaDexus Inc.
Industry: Medical - Products
Q3 sees inline revenue, net loss better than expected - maintain HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Q2 disappointing, near-term visibility lacking - reduce to HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Q2 disappointing, near-term visibility lacking - reduce to HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Q1 results don?t skip a beat, guidance may prove conservative, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
2H15 Opportunities Outweigh Disappointing Q4 results, Price Target to $0.85
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
January Effect Ideas
Provider: Feltl & Company
Price: 10.00
Company: diaDexus Inc.
Industry: Medical - Products
FDA clears PLAC Activity test, reiterate STRONG BUY, $1.45 PT
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Q3 results light on OIG SFA, realignment to reduce operating expenses
Provider: Feltl & Company
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
We are suspending coverage in order to focus on other areas of interest to our institutional clients
Provider: STONEGATE CAPITAL MARKETS
Analyst: TRANG D
Price: 10.00
Company: diaDexus Inc.
Industry: Medical - Products
Q2 results beat, GSK agreement enters second phase, reiterate STRONG BUY
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Darapladib trial disappoints, thesis intact, reiterate STRONG BUY
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Research Update: Results a little under the weather but progressing in its product pipeline
Provider: STONEGATE CAPITAL MARKETS
Analyst: TRANG D
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Q1 misses, guidance raised, reiterate STRONG BUY, price target to $2.40
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Trifecta of positive developments this week, reiterate STRONG BUY, $2.90PT
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
STABILITY data appears to back Lp-PLA2 as marker, reiterate STRONG BUY, $2.90PT
Provider: FELTL & COMPANY
Analyst: HAYNOR B
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Research Update: Signs agreement with Thermo to develop diagnostic test
Provider: STONEGATE CAPITAL MARKETS
Analyst: TRANG D
Price: 25.00
Company: diaDexus Inc.
Industry: Medical - Products
Signs agreement with Thermo to develop diagnostic test
Provider: STONEGATE CAPITAL MARKETS
Analyst: TRANG D
Price: 25.00